- Home
- STTK vs COCH Comparison
STTK vs COCH Comparison
Compare STTK & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- COCH
- Stock Information
- Founded
- STTK 2016
- COCH 1995
- Country
- STTK United States
- COCH United States
- Employees
- STTK N/A
- COCH N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- COCH Blank Checks
- Sector
- STTK Health Care
- COCH Finance
- Exchange
- STTK Nasdaq
- COCH Nasdaq
- Market Cap
- STTK 38.4M
- COCH 31.6M
- IPO Year
- STTK 2020
- COCH N/A
- Fundamental
- Price
- STTK $0.77
- COCH $1.56
- Analyst Decision
- STTK Hold
- COCH Strong Buy
- Analyst Count
- STTK 4
- COCH 2
- Target Price
- STTK $3.00
- COCH $9.25
- AVG Volume (30 Days)
- STTK 229.3K
- COCH 27.9K
- Earning Date
- STTK 08-04-2025
- COCH 08-11-2025
- Dividend Yield
- STTK N/A
- COCH N/A
- EPS Growth
- STTK N/A
- COCH N/A
- EPS
- STTK N/A
- COCH N/A
- Revenue
- STTK $4,606,000.00
- COCH $212,000.00
- Revenue This Year
- STTK N/A
- COCH $5.93
- Revenue Next Year
- STTK N/A
- COCH $17.69
- P/E Ratio
- STTK N/A
- COCH N/A
- Revenue Growth
- STTK 69.65
- COCH N/A
- 52 Week Low
- STTK $0.69
- COCH $1.21
- 52 Week High
- STTK $4.51
- COCH $3.99
- Technical
- Relative Strength Index (RSI)
- STTK 41.85
- COCH 50.89
- Support Level
- STTK $0.73
- COCH $1.60
- Resistance Level
- STTK $0.92
- COCH $1.60
- Average True Range (ATR)
- STTK 0.07
- COCH 0.09
- MACD
- STTK 0.01
- COCH -0.01
- Stochastic Oscillator
- STTK 20.80
- COCH 32.47
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.